Tirzepatide is a dual incretin that produced the largest weight reductions ever measured in a pivotal obesity trial — here is what the SURMOUNT programme actually found.

The short version

Tirzepatide is an FDA-approved prescription medicine — a 39-amino-acid synthetic peptide that mimics two gut hormones at once. Those hormones, called GIP and GLP-1 (incretins — hormones released after a meal that tell the pancreas to make insulin), signal the brain to reduce hunger, slow the stomach, and burn more energy. In obesity trials, adults taking tirzepatide lost an average of 20.9% of their body weight over 72 weeks — more than any previous approved weight-management medicine measured in a major trial ^[4]. It also outperformed the previously best-in-class alternative in a head-to-head study ^[5]. The FDA approved it for type 2 diabetes in May 2022, for weight management in November 2023, and for obstructive sleep apnea in adults with obesity thereafter. Most people tolerate it well, but gastrointestinal effects — especially nausea — are the main reason some stop early. What people report using it, and what to watch for, is on Tirzepatide effects.

What the SURMOUNT programme measured

Tirzepatide's weight-management record begins with SURMOUNT-1, a 72-week phase 3 double-blind randomised controlled trial in 2,539 adults with obesity or overweight plus a weight-related complication. Mean body-weight change at week 72 was −15.0% (5 mg), −19.5% (10 mg), and −20.9% (15 mg) versus −3.1% with placebo ^[4]. More than half of participants on the highest dose lost 20% or more of their starting weight — an effect magnitude the obesity pharmacology literature had not recorded before.

SURMOUNT-4 answered the durability question. After a 36-week open-label lead-in producing a mean 20.9% weight reduction, participants continuing tirzepatide lost a further 5.5% by week 88 — while those switched to placebo regained 14.0% ^[9]. The trial demonstrated that tirzepatide works as a chronic therapy: discontinuation reverses the metabolic benefit. Continued treatment with Tirzepatide research is the mechanism behind sustained results.

SURMOUNT-MAINTAIN, published in 2026, confirmed the maintenance message at a lower 5 mg dose. Participants randomised to 5 mg maintenance at week 60 showed −16.6% total weight change from baseline to week 112, versus −9.9% on placebo (p<0.0001) ^[12]. Even the minimum maintenance dose preserved substantial weight reduction over an additional year.

Tirzepatide results vs semaglutide

SURMOUNT-5, a 2025 phase 3b open-label head-to-head trial in 751 adults with obesity without type 2 diabetes, randomised participants to the maximum tolerated dose of tirzepatide (10 or 15 mg) or the maximum tolerated dose of semaglutide (1.7 or 2.4 mg) once weekly for 72 weeks. The result was clear: −20.2% body weight with tirzepatide versus −13.7% with semaglutide (p<0.001) ^[5]. Tirzepatide also produced greater reductions in waist circumference and higher proportions reaching every 10%, 15%, 20%, and 25% weight-loss threshold. This is the first powered head-to-head efficacy comparison, making tirzepatide weight loss the most closely benchmarked in the class.

The earlier SURPASS-2 comparison in type 2 diabetes reached a similar conclusion for glycaemic endpoints: HbA1c (glycated haemoglobin — a blood marker of average glucose over three months) fell by 2.30 percentage points on tirzepatide 15 mg versus 1.86 percentage points on semaglutide 1 mg at 40 weeks, with tirzepatide non-inferior and superior at all three doses ^[3]. Body weight reductions were also greater at every tirzepatide dose.

Tirzepatide references carries the full source list, including DOIs and PubMed links for all SURMOUNT and SURPASS publications.

Tirzepatide peptide: structure and mechanism

Tirzepatide is a 39-amino-acid fatty-acid-modified peptide — engineered from the backbone of the native GIP hormone, with a C20 fatty diacid (eicosanedioic acid) chain attached to a lysine side chain via a glutamic acid linker. The fatty-diacid arm binds albumin in the bloodstream, slowing clearance and enabling a half-life of approximately five days — the basis of once-weekly subcutaneous dosing ^[7].

In cell-based assays, tirzepatide activated both the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R), but engaged the GIP receptor more fully — an 'imbalanced' dual agonist profile ^[2]. It also showed biased signalling at the GLP-1R, favouring the cAMP pathway over beta-arrestin recruitment, which is proposed to enhance insulin secretion with fewer side effects than a fully balanced GLP-1 agonist. The result of engaging both receptors simultaneously: glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, and reduced appetite — more effect than GLP-1 agonism alone produced in comparative mouse studies ^[1].

For more on what is tirzepatide and the dual-incretin mechanism, see the dedicated explainer.

The safety picture: what the record shows

The most common adverse events in the SURMOUNT and SURPASS trials were gastrointestinal — nausea, diarrhoea, vomiting, and constipation — predominantly during dose escalation, mostly mild to moderate ^[4]. A meta-analysis of 13 obesity trials estimated an overall GI adverse-event rate roughly 2.9-fold above placebo ^[10]. The prescribing information carries a boxed warning regarding thyroid C-cell tumours, based on rodent data; the label contraindicates use in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 ^[6].

The gallbladder and biliary signal is the other major tracked finding: a meta-analysis of nine randomised trials (n=9,871) found a significantly increased composite risk of gallbladder or biliary disease versus controls (relative risk 1.97, 95% CI 1.14–3.42) ^[8]. Pancreatitis risk was not significantly elevated in the same analysis (relative risk 1.46, 95% CI 0.59–3.61), but remains monitored on the label.

The Tirzepatide effects page covers the full safety picture — what people report, what cautions the literature documents, and the historical development that put this compound in clinical use.